Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
Rights acquired to ALS gene therapy from Salk Institute
September 1st, 2003
Ceregene, Inc., announced that it has signed an option agreement with the Salk Institute for Biological Studies for exclusive worldwide rights to its amyotrophic lateral sclerosis (ALS) gene therapy technology. This technology was described in the August 8, 2003, issue of the journal Science and was reported to nearly double the life span of mice in a model of Lou Gehrig disease. Ceregene and the Salk Institute are working collaboratively to establish proof of principle for efficacy in ALS patients by using Ceregene's proprietary gene delivery technology, including the adeno-associated viral (AAV) vector system, to deliver therapeutic growth...
Source: Health & Medicine Week (2003-09-01)
|
